Interleukin gains patent for sepsis gene:
This article was originally published in Clinica
Executive Summary
Interleukin Genetics has gained a US patent relating to a genetic marker that could lead to a DNA test for identifying patients who have a significantly increased risk of dying from sepsis. The Waltham, Massachusetts-based company has discovered that common variations in the human IL-1B gene are associated with a much higher risk of dying from the infection, which affects tens of thousands of people in the US annually.